Opportunity Information: Apply for RFA HL 11 013
Apply for RFA HL 11 013
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Core Clinical Centers (U10)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.395 Cancer Treatment Research 93.839 Blood Diseases and Resources Research.
- This funding opportunity was created on Aug 11, 2010 and posted on Aug 11, 2010.
- Applicants must submit their applications by Oct 13, 2010. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $115,000.00 in funding.
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Tribally Controlled Colleges and Universities (TCCUs) .
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Core Clinical Centers (U10) opportunity (RFA HL 11 013) is a National Institutes of Health funding announcement led by the National Heart, Lung, and Blood Institute (NHLBI) together with the National Cancer Institute (NCI). It supports a national, multi center clinical trials network focused on hematopoietic stem cell transplantation (HSCT), commonly referred to as blood and marrow transplantation. The overall goal is to run well coordinated clinical studies that efficiently compare new treatment approaches and patient management strategies, with the intent of improving outcomes for both pediatric and adult transplant patients. The announcement is described as an open competition intended to renew an existing network, meaning it is not creating the concept of the network from scratch, but rather recompeting and refreshing the set of participating clinical centers that will carry the work forward.
Funding is provided through the NIH U10 Cooperative Agreement mechanism. In practice, a U10 signals a cooperative research arrangement where the NIH plays an active stewardship role beyond standard grant oversight. Awardees are expected to function as part of a coordinated program, align with network wide protocols and priorities, and collaborate closely with NIH and with other funded components of the network. The clinical centers funded under this FOA are designated as Core Clinical Centers, which are the sites responsible for conducting the actual HSCT clinical trials work: enrolling and treating participants, adhering to shared study protocols, collecting high quality clinical data, and contributing clinical expertise to protocol development and trial operations across the network.
NHLBI and NCI planned to commit up to $63.5 million in total costs over a six year project period for this program. The anticipated scope was up to 19 Core Clinical Centers, along with a separate Data Coordinating Center (DCC) to support network operations and data management. Applicants interested in serving as the DCC were directed to a companion funding announcement (RFA HL 11 028), indicating that the data coordination function was competed and funded separately from the clinical center awards. The listed award ceiling in the opportunity synopsis is $115,000, but the FOA also makes clear the larger total program commitment across multiple awards over six years.
Eligibility for this opportunity was broad and included many organizational types that could credibly operate as transplant clinical research centers. Eligible applicants included public and state controlled institutions of higher education, private institutions of higher education, nonprofit organizations with or without 501(c)(3) status (other than institutions of higher education), and for profit organizations other than small businesses. The eligibility language also explicitly included a range of mission focused and community aligned institutions such as Historically Black Colleges and Universities (HBCUs), Hispanic Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, faith based or community based organizations, and eligible federal agencies. There was no cost sharing or matching requirement noted.
Administratively, the opportunity was categorized as discretionary funding and used the cooperative agreement funding instrument type, with activity areas tied to education and health. It was associated with CFDA program areas 93.395 (Cancer Treatment Research) and 93.839 (Blood Diseases and Resources Research), reflecting the joint cancer and blood disease focus inherent to HSCT research. The FOA was posted on August 11, 2010, with an application due date (closing date) of October 13, 2010, and it was later archived on November 13, 2010. The full announcement was hosted through the NIH grants guide, and general technical assistance contacts were provided through the NIH Office of Extramural Research (OER) webmaster for access or linking issues.
In plain terms, this grant competition was aimed at selecting a set of highly capable transplant centers to act as the clinical backbone of the BMT CTN. The expectation was that these centers would collaborate in running multi site HSCT trials, generate reliable evidence about novel transplant strategies and supportive care approaches, and do so in a way that is faster and more comparable than isolated single center studies. The companion DCC award would provide the centralized infrastructure needed to coordinate protocols, manage and analyze study data, and support consistent network wide trial execution.
Frequently Asked Questions (FAQs)
What is the BMT CTN Core Clinical Centers (U10) opportunity (RFA HL 11 013)?
This opportunity is a National Institutes of Health (NIH) funding announcement to support Core Clinical Centers within the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). The network focuses on hematopoietic stem cell transplantation (HSCT), commonly known as blood and marrow transplantation, and is built to run coordinated, multi-center clinical trials in this area.
Which NIH institutes lead this funding announcement?
The announcement is led by the National Heart, Lung, and Blood Institute (NHLBI) together with the National Cancer Institute (NCI).
What is the main purpose of funding Core Clinical Centers?
The purpose is to support transplant clinical research centers that can serve as the clinical backbone of a national, multi-center HSCT trials network. These centers are expected to conduct well-coordinated clinical studies that efficiently compare new treatment approaches and patient management strategies, with the goal of improving outcomes for both pediatric and adult transplant patients.
What does HSCT stand for, and what does it relate to in this announcement?
HSCT stands for hematopoietic stem cell transplantation. In this announcement, HSCT refers to blood and marrow transplantation clinical trials and related patient management strategies studied through the BMT CTN network.
Is this opportunity creating a brand-new network?
No. The announcement is described as an open competition intended to renew an existing network. In practical terms, it recompetes and refreshes the set of participating clinical centers rather than creating the network concept from scratch.
What type of NIH funding mechanism is used?
Funding is provided through the NIH U10 Cooperative Agreement mechanism.
What does a U10 Cooperative Agreement imply for how the program is run?
A U10 indicates a cooperative research arrangement where NIH has an active stewardship role beyond standard grant oversight. Awardees are expected to function as part of a coordinated program, align with network-wide protocols and priorities, and collaborate closely with NIH and other funded network components.
What are Core Clinical Centers expected to do under this program?
Core Clinical Centers are the sites responsible for conducting the actual HSCT clinical trials work. Based on the announcement description, this includes enrolling and treating participants, adhering to shared study protocols, collecting high-quality clinical data, and contributing clinical expertise to protocol development and trial operations across the network.
How is the BMT CTN structured under this funding approach?
The anticipated scope includes up to 19 Core Clinical Centers, plus a separate Data Coordinating Center (DCC) that supports network operations and data management.
Is the Data Coordinating Center (DCC) funded under the same announcement?
No. Applicants interested in serving as the DCC were directed to a companion funding announcement (RFA HL 11 028). The DCC function was competed and funded separately from the clinical center awards.
What is the role of the Data Coordinating Center (DCC) as described here?
The DCC provides centralized infrastructure to coordinate protocols, manage and analyze study data, and support consistent network-wide trial execution.
How much funding was planned for this program overall?
NHLBI and NCI planned to commit up to $63.5 million in total costs over a six-year project period for the overall program.
How long is the project period?
The planned project period is six years.
How many awards were anticipated for Core Clinical Centers?
The anticipated scope was up to 19 Core Clinical Centers (with the DCC funded separately under a companion announcement).
Why does the synopsis show an award ceiling of $115,000 if the overall commitment is much larger?
The opportunity synopsis lists an award ceiling of $115,000, while the announcement also states a larger total program commitment across multiple awards over six years. The information provided indicates that the program’s planned total investment spans multiple cooperative agreement awards and program components rather than reflecting a single-center total.
Who is eligible to apply?
Eligibility is broad and includes organizations that could credibly operate as transplant clinical research centers. Eligible applicants include:
- Public and state-controlled institutions of higher education
- Private institutions of higher education
- Nonprofit organizations with or without 501(c)(3) status (other than institutions of higher education)
- For-profit organizations other than small businesses
- Eligible federal agencies
Are any mission-focused or community-aligned institutions explicitly included as eligible?
Yes. The eligibility language explicitly includes Historically Black Colleges and Universities (HBCUs), Hispanic Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and faith-based or community-based organizations (as applicable within the eligible categories described).
Is cost sharing or matching required?
No cost sharing or matching requirement is noted in the information provided.
What kind of funding is this categorized as?
Administratively, it is categorized as discretionary funding and uses the cooperative agreement funding instrument type.
What activity areas does the opportunity align with?
The activity areas are tied to education and health.
What CFDA program areas are associated with this opportunity?
The opportunity is associated with CFDA 93.395 (Cancer Treatment Research) and 93.839 (Blood Diseases and Resources Research).
When was the FOA posted, and when was the application due?
The FOA was posted on August 11, 2010. The application due date (closing date) was October 13, 2010.
Is this funding announcement still open?
No. The announcement was later archived on November 13, 2010.
Where was the full announcement hosted?
The full announcement was hosted through the NIH grants guide.
Who was listed for general technical assistance related to access or linking issues?
General technical assistance contacts were provided through the NIH Office of Extramural Research (OER) webmaster for access or linking issues.
In practical terms, what is the expected impact of selecting Core Clinical Centers?
The intent is to enable highly capable transplant centers to collaborate in running multi-site HSCT trials, generating reliable evidence about novel transplant strategies and supportive care approaches. The network approach is meant to be faster and more comparable than isolated single-center studies because it uses shared protocols and coordinated operations across multiple sites.
Browse more opportunities from the same category: Education Health
Next opportunity: Americas Marine Highway Grants
Previous opportunity: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Data Coordinating Center (U10)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HL 11 013
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HL 11 013) also looked into and applied for these:
| Funding Opportunity |
|---|
| Coordinating Center for the Barretts Esophagus Translational Research Network (U01) Apply for RFA CA 10 015 Funding Number: RFA CA 10 015 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Barretts Esophagus Translational Research Network (U54) Apply for RFA CA 10 014 Funding Number: RFA CA 10 014 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Exceptional, Unconventional Research Enabling Knowledge Acceleration (EUREKA) (R01) Apply for RFA GM 11 003 Funding Number: RFA GM 11 003 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Neuroscience Research on Drug Abuse (R01) Apply for PA 10 268 Funding Number: PA 10 268 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Neuroscience Research on Drug Abuse (R21) Apply for PA 10 269 Funding Number: PA 10 269 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Neuroscience Research on Drug Abuse (R03) Apply for PA 10 270 Funding Number: PA 10 270 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Early Career Award in Chemistry of Drug Abuse and Addiction (ECHEM) NIDA (R21/R33) Apply for PAS 10 274 Funding Number: PAS 10 274 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Pharmacological Development of Treatment Agents and Formulations for Tobacco Dependence (STTR R41 Apply for RFA DA 11 004 Funding Number: RFA DA 11 004 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Developing and Improving Institutional Animal Resources (G20) Apply for RFA RR 10 011 Funding Number: RFA RR 10 011 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Innovative Emerging Molecular Analysis Technologies (SBIR R43/R44) Apply for RFA CA 10 013 Funding Number: RFA CA 10 013 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Assay Development for High Throughput Screening for Nicotinic Receptor Subunits (R21) Apply for RFA DA 11 007 Funding Number: RFA DA 11 007 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Core Infrastructure and Methodological Research for Cancer Epidemiology Cohorts (U01) Apply for PAR 10 283 Funding Number: PAR 10 283 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Cancer Diagnostic and Therapeutic Agents Enabled by Nanotechnology (SBIR U43/U44) Apply for PAR 10 286 Funding Number: PAR 10 286 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| 2011 NIDA Avant Garde Award Program for HIV/AIDS Research (DP1) Apply for RFA DA 11 002 Funding Number: RFA DA 11 002 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Pre Application for the 2011 NIDA Avant Garde Award Program for HIV/AIDS Research (X02) Apply for PAR 10 287 Funding Number: PAR 10 287 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Resource Related Research Projects for Development of Animal Models and Related Materials (R24) Apply for PAR 10 289 Funding Number: PAR 10 289 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Research on Malignancies in the Context of HIV/AIDS (R01) Apply for PA 10 290 Funding Number: PA 10 290 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Research on Malignancies in the Context of HIV/AIDS (R21) Apply for PA 10 291 Funding Number: PA 10 291 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Tumor Microenvironment Network (TMEN) (U54) Apply for RFA CA 10 021 Funding Number: RFA CA 10 021 Agency: National Institutes of Health Category: Education Health Funding Amount: $700,000 |
| Animal and Biological Material Resource Centers (P40) Apply for PAR 11 001 Funding Number: PAR 11 001 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HL 11 013", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.